Jafra Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Jafra Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-10,000	Closed	-$455K	–	70
2018 Q2	$455K	Buy	+10,000	New	+$486K	0.16%	82
2018 Q1	–	Sell	-21,240	Closed	-$1.44M	–	115
2017 Q4	$1.44M	Sell	21,240 -22,052	-51%	-$1.54M	0.41%	63
2017 Q3	$3.57M	Buy	43,292 +18,755	+76%	+$1.49M	1.33%	30
2017 Q2	$2.3M	Buy	24,537 +6,922	+39%	+$424K	0.85%	48
2017 Q1	$1.12M	Buy	+17,615	New	+$1.07M	0.45%	47

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Jafra Capital Management's CLVS Position: Q3 2018 in Review

Jafra Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2018, closing a stake of 10,000 shares — an estimated $455K sold.

Jafra Capital Management first reported a position in CLVS in Q1 2017 and held it in 5 quarters. The position peaked at $3.57M in Q3 2017. 192 funds tracked by Wall St. Rank hold CLVS as of Q3 2018.

Jafra Capital Management reported no remaining Clovis Oncology, Inc. position as of Q3 2018 after selling out during the quarter.
Jafra Capital Management sold 10,000 Clovis Oncology, Inc. shares in Q3 2018, an estimated $455K.
Jafra Capital Management first reported a position in Clovis Oncology, Inc. in Q1 2017 and held it in 5 quarters.
Jafra Capital Management's Clovis Oncology, Inc. position peaked at $3.57M in Q3 2017.
192 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2018.

Based on Jafra Capital Management's 13F filing for Q3 2018.